Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema

Eye

Volumn 24, Issue 8, 2010, Pages 1325-1330

  Forte, R ^a   Cennamo, G L ^a   Finelli, M ^a   Farese, E ^a   D'Amico, G ^a   Nicoletti, G ^a   De Crecchio, G ^a   Cennamo, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

anti VEGF; corticosteroids; diabetic oedema; IOP; laser therapy

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; DIABETIC MACULAR EDEMA; DIFFUSE DIABETIC MACULAR EDEMA; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL TRIAMCINOLONE COMBINED WITH MACULAR LASER GRID; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 77955597375     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.23     Document Type: Article

References (38)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91(12): 1464-1474.
2. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology 1988; 95(10): 1340-1348.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103(12): 1796-1806.
4. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94(7): 761-774.
5. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995; 113(9): 1144-1155.
6. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44(5): 2155-2162.
7. Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Noma H et al. Vitreous levels of pigment epitheliumderived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113(2): 294-301.
8. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132(3): 425-427. (Pubitemid 32768624)
9. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109(5): 920-927.
10. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121(1): 57-61. (Pubitemid 36401766)
11. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004; 88(9): 1131-1136.
12. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111(2): 218-224; discussion 224-1215
13. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters 3rd GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110(4): 681-686.
14. Karacorlu M, Karacorlu SA, Ozdemir H, Senturk F. Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion. Retina 2007; 27(8): 1026-1030.
15. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn Jr HW, Lee JE, Mavrofrides EC et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006; 26(8): 889-895.
16. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9): 999-1005.
17. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28(8): 1053-1060.
18. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan- American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114(4): 743-750.
19. Aiello LP, Brucker AJ, Chang S, Cunningham Jr ET, DAmico DJ, Flynn Jr HW et al. Evolving guidelines for intravitreous injections. Retina 2004; 24(5 Suppl): S3-19.
20. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27(9): 1187-1195.
21. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116(6): 1142-1150.
22. Rensch F, Spandau UH, Wickenhauser A, Jonas JB. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol 2009. [Epub ahead of print 6 February 2009].
23. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145(5): 854-861.
24. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92(1): 76-80.
25. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008; 246(4): 483-489. (Pubitemid 351447960)
26. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114(3): 525-536.
27. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114(10): 1860-1867.
28. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular agerelated macular degeneration: one-year results. Arch Ophthalmol 2003; 121(5): 667-673.
29. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138(1): 158-160.
30. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2006; 113(5): 800-804.
31. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140(4): 695-702.
32. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DTet al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007; 114(12): 2162-2167.
33. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124(5): 653-658.
34. Noma H, Funatsu H, Yamasaki M, Tsukamo H, Mimura T, Sone T et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008; 22(1): 42-48.
35. Butcher JM, Austin M, McGalliard J, Bourke RD. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ 1994; 309(6946): 43.
36. Armaly MF. Statistical Attributes of the Steroid Hypertensive Response in the Clinically Normal Eye. I. The Demonstration of Three Levels of Response. Invest Ophthalmol 1965; 4: 187-197.
37. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 1279: 1101-1114.
38. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR et al. Diabetic Retinopathy Clinical Research Network (DRC.Rnet). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251.